Welcome to Hodoodo Chemicals

Loxoprofen sodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H525460

CAS#: 80382-23-6 (sodium)

Description: Loxoprofen is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group. loxoprofen is a non-selective cyclooxygenase inhibitor, and works by reducing the synthesis of prostaglandins from arachidonic acid.

Chemical Structure

Loxoprofen sodium

CAS# 80382-23-6 (sodium)

Instruction

Theoretical Analysis

Hodoodo Cat#: H525460
Name: Loxoprofen sodium
CAS#: 80382-23-6 (sodium)
Chemical Formula: C15H17NaO3
Exact Mass: 0.00
Molecular Weight: 268.288
Elemental Analysis: C, 67.15; H, 6.39; Na, 8.57; O, 17.89

Price and Availability

Size	Price	Availability
5g	USD 250	2 Weeks
10g	USD 400	2 Weeks
25g	USD 700	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 80382-23-6 (sodium) 68767-14-6 (free acid) 226721-96-6 (sodium hydrate),

Synonym: Loxoprofen; CS-600; CS600; CS 600.

IUPAC/Chemical Name: alpha-Methyl-4-((2-oxocyclopentyl)methyl)benzeneacetate sodium salt

InChi Key: WORCCYVLMMTGFR-UHFFFAOYSA-M

InChi Code: InChI=1S/C15H18O3.Na/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16;/h5-8,10,13H,2-4,9H2,1H3,(H,17,18);/q;+1/p-1

SMILES Code: O=C([O-])C(C)C1=CC=C(CC2C(CCC2)=O)C=C1.[Na+]

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 268.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Tak JW, Gupta B, Thapa RK, Woo KB, Kim SY, Go TG, Choi Y, Choi JY, Jeong JH, Choi HG, Yong CS, Kim JO. Preparation and Optimization of Immediate Release/Sustained Release Bilayered Tablets of Loxoprofen Using Box-Behnken Design. AAPS PharmSciTech. 2016 Jul 11. [Epub ahead of print] PubMed PMID: 27401334.

2: Kato M, Sasaki S, Sekimoto Y, Arano N, Jo H, Suina K, Kuriyama S, Muraki K, Nagashima O, Yoshioka Y, Tominaga S, Takahashi K. Loxoprofen-induced interstitial pneumonia: a case report. J Med Case Rep. 2016 May 25;10(1):128. doi: 10.1186/s13256-016-0919-2. PubMed PMID: 27225339; PubMed Central PMCID: PMC4880964.

3: Katagiri K. Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis. J Dermatol. 2016 Mar 11. doi: 10.1111/1346-8138.13349. [Epub ahead of print] PubMed PMID: 26970197.

4: Onda A, Ogoshi A, Itoh M, Nakagawa T, Kimura M. Comparison of the effects of treatment with celecoxib, loxoprofen, and acetaminophen on postoperative acute pain after arthroscopic knee surgery: A randomized, parallel-group trial. J Orthop Sci. 2016 Mar;21(2):172-7. doi: 10.1016/j.jos.2015.11.005. Epub 2016 Feb 14. PubMed PMID: 26888227.

5: Kumagai T, Yamaguchi N, Hirai H, Kojima S, Kodani Y, Hashiguchi A, Haida M, Nakamura M. Loxoprofen sodium induces the production of complement C5a in human serum. Int Immunopharmacol. 2016 Apr;33:55-62. doi: 10.1016/j.intimp.2016.01.025. Epub 2016 Feb 6. PubMed PMID: 26854577.

6: Nakai N, Katoh N. A case of fixed drug eruption caused by loxoprofen sodium hydrate. Allergol Int. 2015 Oct;64(4):377-8. doi: 10.1016/j.alit.2015.04.007. Epub 2015 May 15. PubMed PMID: 26433535.

7: Fujimori S, Hanada R, Hayashida M, Sakurai T, Ikushima I, Sakamoto C. Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment: A Double-blind, Randomized, Controlled Trial. J Clin Gastroenterol. 2016 Mar;50(3):218-26. doi: 10.1097/MCG.0000000000000372. PubMed PMID: 26166140.

8: Hiroshima Y, Kato T, Tajima K. Regression of diffuse large B-cell lymphoma in

sphenoid and ethmoid sinuses following treatment with loxoprofen. Leuk Lymphoma.

2016;57(3):721-3. doi: 10.3109/10428194.2015.1070154. Epub 2015 Jul 7. PubMed PMID: 26148875.

9: Sawamura R, Kazui M, Kurihara A, Izumi T. Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats. Pharmazie. 2015 Feb;70(2):74-80. PubMed PMID: 25997245.

10: Sekiguchi H, Inoue G, Nakazawa T, Imura T, Saito W, Uchida K, Miyagi M, Takahira N, Takaso M. Loxoprofen sodium and celecoxib for postoperative pain in patients after spinal surgery: a randomized comparative study. J Orthop Sci. 2015 Jul;20(4):617-23. doi: 10.1007/s00776-015-0726-4. Epub 2015 Apr 25. PubMed PMID:

25911562.

11: Chen X, Matsuzawa T, Hitsu E, Zhong W, Qian Z, Jiang J, Hu P. Modeling the dermatopharmacokinetic profile of two loxoprofen patches for bioequivalence confirmation. Int J Clin Pharmacol Ther. 2015 May;53(5):412-3. doi: 10.5414/CP202281. PubMed PMID: 25828640.

12: Sawamura R, Sakurai H, Wada N, Nishiya Y, Honda T, Kazui M, Kurihara A, Shinagawa A, Izumi T. Bioactivation of loxoprofen to a pharmacologically active metabolite and its disposition kinetics in human skin. Biopharm Drug Dispos. 2015 Mar 12. doi: 10.1002/bdd.1945. [Epub ahead of print] PubMed PMID: 25765700.

13: Hui M, Quan P, Yang Y, Fang L. The effect of ion-pair formation combined with penetration enhancers on the skin permeation of loxoprofen. Drug Deliv. 2016 Jun;23(5):1550-7. doi: 10.3109/10717544.2014.981768. Epub 2014 Nov 11. PubMed PMID: 25386739.

14: Yamashita Y, Sano N, Shimohira D, Danjo A, Goto M. A parallel-group comparison study of celecoxib with loxoprofen sodium in third mandibular molar extraction patients. Int J Oral Maxillofac Surg. 2014 Dec;43(12):1509-13. doi: 10.1016/j.ijom.2014.09.002. Epub 2014 Sep 28. PubMed PMID: 25270186.

15: Chen X, Zhao Q, Hitsu E, Jiang J, Zhong W, Matsuzawa T, Hu P. Dermatopharmacokinetic bioequivalence study of two types of topical patches containing loxoprofen sodium. Int J Clin Pharmacol Ther. 2014 Oct;52(10):927-32.

doi: 10.5414/CP202165. PubMed PMID: 25250614.

16: Mu R, Bao CD, Chen ZW, Zheng Y, Wang GC, Zhao DB, Hu SX, Li YJ, Shao ZW, Zhang ZY, Xiao WG, Zhang W, Li ZG. Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial. Clin Rheumatol. 2016 Jan;35(1):165-73. doi: 10.1007/s10067-014-2701-4. Epub 2014 Jun 14. PubMed PMID: 24924603.

17: Sawamura R, Kazui M, Kurihara A, Izumi T. Absorption, distribution, metabolism and excretion of loxoprofen after dermal application of loxoprofen gel to rats. Xenobiotica. 2014 Nov;44(11):1026-38. doi: 10.3109/00498254.2014.926571. Epub 2014 Jun 11. PubMed PMID: 24916900.

18: Kikuchi H, Aoyagi M, Nagahama K, Yajima Y, Yamamura C, Arai Y, Hirasawa S, Aki S, Inaba N, Tanaka H, Tamura T. Nephrotic-range proteinuria and interstitial

nephritis associated with the use of a topical loxoprofen patch. Intern Med. 2014;53(11):1131-5. Epub 2014 Jun 1. PubMed PMID: 24881736.

19: Yue Z, Shi J, Jiang P, Sun H. Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1154-9. doi: 10.1002/pds.3626. Epub 2014 Apr 30. PubMed PMID: 24788910.

20: Fukiya Y, Yoshizumi M, Saito M, Matsumoto-Miyai K, Nimura T, Kawatani M. Synergistic effects of loxoprofen and glycine on the micturition reflex in conscious rats. Biomed Res. 2014;35(1):17-23. PubMed PMID: 24573198.